Deutsche Bank remains bullish on the CRO sector, viewing 2Q26 as showing “green, green, green” recovery signals
AI summary card
Deutsche Bank remains bullish on the CRO sector, viewing 2Q26 as showing “green, green, green” recovery signals
The report believes the CRO industry is improving across biotechnology financing, pharmaceutical outsourcing demand, licensing transactions, and valuation recovery, while AI/ML is more likely to drive efficiency gains and support margins than pose a near-term replacement threat.
- Biopharmaceutical equity financing reached approximately $27 billion in 2Q26, the third-highest quarter on record, and could reach approximately $80 billion for the full year based on the 1H26 run rate.
- The report states that CRO stocks rose an average of 17% over the past month, but remained under pressure from the beginning of the year through the pre-earnings season in May, leaving room for valuation and 2027 expectation recovery.
- Deutsche Bank believes concerns about CRO replacement driven by AI/ML are overstated, and that easing AI fears alone could drive 1-2x valuation multiple recovery.
- Industry research indicates that EBP customer RFPs and bookings are improving, demand from large and mid-sized pharmaceutical companies is stable, and more preclinical and early-stage outsourcing is flowing to China and India.
- Among the key stocks, IQV is viewed as an opportunity for sentiment recovery and EPS upside, while CRL and ICLR are also expected to deliver earnings upside or modest positive revisions.
Report interpretation
Overview
This report is Deutsche Bank’s portfolio manager summary of the CRO and biopharmaceutical services sectors in 2Q26. Its core conclusion is that industry fundamentals are steadily recovering: biotechnology financing is improving, the quality of RFPs and bookings is rising, large pharmaceutical companies’ R&D spending remains resilient, licensing transactions and M&A activity are recovering, and AI/ML has not materially eroded CRO demand but may instead improve efficiency and support margins.
Core views
Deutsche Bank maintains a positive view of CRO stocks and believes there is a dual opportunity for upward estimate revisions and valuation recovery from 2Q26 through 2027. The report is particularly positive on IQV’s potential for sentiment recovery, AI capabilities, and EPS upside, and also sees execution potential at CRL as preclinical demand recovers and margins improve in 2H26. ICLR is still viewed as having potential for positive revisions. Although target prices for MEDP and FTRE were raised, their ratings remain Hold, mainly due to cancellation rates, growth sustainability, leverage, or valuation constraints.
Analysis framework
The report combines Deutsche Bank earnings forecasts, consensus expectations, buy-side expectations, industry channel research, communications with company management, valuation multiple comparisons, and macro industry indicators. Key analytical areas include 2Q26 book-to-bill, bookings, 2026/2027 revenue and EPS forecasts, AI’s impact on the CRO business model, biotechnology financing, pharmaceutical R&D budgets, licensing transactions, M&A, government research funding, and early-stage outsourcing trends in China and India.
Methodology notes
Assess the CRO demand cycle through financing, RFPs, bookings, book-to-bill, outsourcing penetration, and margin trends.
The report treats improved 2Q26 financing, recovering EBP demand, stable large-pharma demand, increased preclinical outsourcing, and stabilizing pricing as key evidence of industry recovery.
Derive target prices using 2026E EPS or 2027E EBITDA multiples and compare them with five-year historical averages and peer valuations.
The MEDP target price is based on 28x 2026E EPS, the CRL target price on 13.5x 2027E EBITDA, the FTRE target price on 11x 2027E EBITDA, and the IQV target price on 13x 2027 EBITDA.
Assess AI/ML’s impact on CRO demand, costs, efficiency, margins, and clients’ outsourcing decisions.
The report believes AI is more likely to enhance CRO efficiency and be used by large pharmaceutical companies to accelerate and improve quality, while the near-term risk of fully replacing human clinical monitoring or CRO services is limited.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- IQVIA (IQV)Core beneficiary, rated Buy, target price $240
- Strengths
- AI-related concerns are considered excessive. IQV has proprietary data and an early-mover advantage in deploying AI agents, with 19 of the 20 largest pharmaceutical companies already using Iqvia agents.
- Weaknesses
- Down approximately 8% year to date, with the market concerned about AI disintermediation and the pace of margin performance in 2026.
- Comparison
- The report says it currently trades at approximately 11x 2027E EBITDA, below the five-year average of approximately 13x, providing room for valuation recovery.
- Risks
- Changes in large-pharma pipeline priorities, cuts to R&D spending, weakening biotechnology financing, declining outsourcing penetration, pricing pressure, share loss, regulatory and geopolitical risks, and margin pressure.
- Charles River Laboratories (CRL)Key preferred name, rated Buy, target price raised to $260
- Strengths
- Preclinical demand is recovering, 2H26 operating margin improvement is expected to exceed 500bps, the company has completed two divestitures, and further cost-efficiency opportunities remain.
- Weaknesses
- Recovery still requires continued execution by the company, while the current valuation is already close to the five-year average.
- Comparison
- The target price is based on 13.5x 2027E EBITDA, above the previous 12.5x, reflecting end-market improvement and industry multiple recovery.
- Risks
- Valuation upside could be limited if organic growth does not turn positive, improving RFPs fail to convert into revenue, the NAMs market opportunity falls short of expectations, or AI efficiency gains are implemented more slowly than expected.
- ICON (ICLR)Potential beneficiary of positive revisions, rated Buy, target price $188
- Strengths
- The report believes ICLR remains supported by book-to-bill and bookings expectations and is one of the CROs expected to benefit from improving industry demand.
- Weaknesses
- Uncertainty remains around 2026 guidance and revenue recognition issues.
- Comparison
- The target price is based on 11x 2027 EBITDA, which the report says represents a significant discount to the historical trading range to reflect uncertainty.
- Risks
- Revenue recognition issues, concerns about AI disintermediation, industry multiple contraction, and the risk that growth fails to materialize.
- Medpace (MEDP)Rated Hold, target price raised to $480
- Strengths
- Benefits from improving biotechnology financing, market share opportunities, margin expansion, and capital allocation.
- Weaknesses
- The cancellation rate is at its highest level in more than a year, and the market is focused on whether future growth rates can be sustained.
- Comparison
- The target price is based on 28x 2026E EPS, above the previous 25x and close to the five-year average forward multiple.
- Risks
- Rising cancellation rates, margin compression caused by employee expansion, scale challenges, competitive disruption, slower financing or R&D spending, and customer concentration risk.
- Fortrea (FTRE)Rated Hold, target price raised to $18
- Strengths
- Cost savings, improving EBP bookings, and AI opportunities may provide support.
- Weaknesses
- Revenue growth headwinds and high leverage create elevated financial risk.
- Comparison
- The target price is based on 11x 2027E EBITDA, still at a discount to the CRO peer median.
- Risks
- Leverage pressure, weaker-than-expected revenue growth, insufficient margin expansion, and an EBP demand recovery below expectations.
- Concentra (CON)Rated Buy, target price $32
- Strengths
- Related to economic data, market expansion, and new market opportunities.
- Weaknesses
- The report provides relatively limited company-specific detail.
- Comparison
- The table shows a current price of approximately $31.40 and a target price of $32, implying approximately 2% upside.
- Risks
- Weaker economic data, market expansion below expectations, and slower-than-expected progress in new markets.
- Maravai Life Sciences (MRVI)Rated Buy, target price $6
- Strengths
- Demand indicators, new product adoption, EBITDA margin expansion, and AI-related products are key areas of focus.
- Weaknesses
- Its smaller market capitalization means that earnings and demand improvement still require validation.
- Comparison
- The table shows a current price of approximately $5.97 and a target price of $6, implying approximately 1% upside.
- Risks
- Insufficient demand improvement, slower new product adoption, EBITDA margin expansion below expectations, and AI product commercialization below expectations.
Key data
- 2Q26 Biopharmaceutical Equity Financing$27bThe report calls it the third-highest quarter on record, with approximately $80b for the full year based on the 1H26 run rate.
- 2Q26 Licensing Transaction Value$79b, YoY +70%Above $47b in 2Q25; upfront payments were approximately $5b, up 20% from approximately $4b in 2Q25.
- Recent CRO Stock PerformanceAverage +17% over the past monthThis contrasts with the sector’s approximately 23% decline from the beginning of the year through the pre-earnings season in May.
- Buy-Side 2Q26 Book-to-Bill ExpectationsAverage approximately 0.05x above sell-side consensusBuy-side expectations for ICLR were as high as approximately 1.30x, while the low end of bullish MEDP expectations was approximately 1.05x.
- Early-Stage Outsourcing Trend in China/India+5-10% workload, costs 20-35% lower, approximately 40% fasterIndustry experts said more preclinical and early-stage work is flowing to China and India.
- IQV Valuation11x 2027E EBITDAThe report says this represents an approximately 3x discount to the five-year average of approximately 13x, making it an attractive entry point.
- CRL 2H26 Margin Improvement>+500bpsThe company has good visibility into operating margin improvement in 2H26 relative to 1H26.
Impact & implications
If the report’s view proves correct, the CRO sector could benefit from upward revisions to 2027 earnings expectations, recovery in industry valuation multiples, and AI-driven efficiency gains. From an investment perspective, prior market concerns about AI replacement, uncertainty around cyclical recovery, and margin pressure may have been excessive. Leaders such as IQV, CRL, and ICLR may benefit more readily, although MEDP’s cancellation rate, FTRE’s leverage, and revenue growth pressure still warrant close monitoring.
Risks
- Changes in large-pharma pipeline priorities or cuts to R&D spending could suppress CRO orders and revenue growth.
- If the biotechnology financing environment weakens again, EBP customer RFPs, bookings, and clinical trial starts could be affected.
- If AI/ML accelerates the replacement of certain CRO activities or forces service prices lower, revenue and margins could weaken.
- Pricing pressure, changes in business mix, and low-quality bookings could continue to weigh on 2026 margins.
- Regulatory, geopolitical, and U.S. government research funding policy volatility could affect R&D budgets and the geographic distribution of outsourcing.
- Company-specific risks such as MEDP’s cancellation rate, FTRE’s high leverage, and ICLR’s revenue recognition issues could limit a broad-based sector rally.
What to watch
- Whether sequential improvement in 2Q26 book-to-bill, bookings, and RFPs across companies continues.
- Whether exit growth in 4Q26 can support a return to long-term-plan CRO growth in 2027.
- Whether improved financing for EBP customers translates into actual orders and revenue growth.
- Whether efficiency gains from AI agents, clinical monitoring, medical writing, statistical analysis, and data management are retained by CROs or passed on to customers.
- Whether CRL can deliver more than 500bps of margin improvement and positive organic growth in 2H26.
- IQV disclosures on AI-related revenue, customer adoption, and the margin bridge.
- Changes in the U.S. NIH budget and global government research funding policies.
- The impact of higher early-stage outsourcing exposure to China and India on U.S. CRO pricing and the competitive landscape.